REGENXBIO, Inc.

REGENXBIO, Inc.

REGENXBIO, Inc.

Overview
Date Founded

2008

Headquarters

9600 Blackwell Road,Suite 210,Rockville, MD 20850

Type of Company

Public

Employees (Worldwide)

192

Industries

Biotechnology
Medical Products & Equipment
Pharmaceuticals

Company Description

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Contact Data
Trying to get in touch with decision makers at REGENXBIO, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Scientific Founder

President, Chief Executive Officer, Executive Director

Senior Vice President & Chief Financial Officer

Senior Vice President & General Counsel

Senior Vice President, Product Development & Chief Technology Officer

Chief Scientific Officer & Senior Vice President

Chief Medical Officer & Senior Vice President

Senior Vice President, Intellectual Property

Senior Vice President, Human Resources

Senior Vice President-Commercial Strategy & Operations

Board of Directors

Chief Executive Officer at Windmil Therapeutics, Inc.

Professional at REGENXBIO, Inc.

Managing Member at Care Capital III LLC

Professional at REGENXBIO, Inc.

Consultant at Sunesis Pharmaceuticals, Inc.

Chief Executive Officer at DBV Technologies

Co-Founder at Dimension Therapeutics, Inc.

President, Chief Executive Officer & Director at Cedilla Therapeutics, Inc.

Paths to REGENXBIO, Inc.
Potential Connections via
Relationship Science
You
REGENXBIO, Inc.
Owners & Shareholders
Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Goldstein & McClintock LLLP is a cutting-edge boutique law firm representing a broad array of sophisticated clients in a wide variety of matters across the nation. In addition to handling all aspects of corporate restructuring matters through its pre-eminent corporate restructuring, bankruptcy, and creditors’ rights practice, G&M attorneys regularly assist clients with a wide variety of transactional and commercial litigation matters. G&M’s partners – all of whom have worked on numerous complex matters, including at some of the top corporate law firms in the U.S. – are well known in both the regional and national bankruptcy bar, and have represented a host of constituencies in some of the country’s most significant cases. Whatever the matter, G&M is unique in being able to offer clients affordable “white-shoe” advice combined with the accessibility and individual attention of a boutique law practice. Although G&M's attorneys are well versed in a broad spectrum of matters – from corporate, finance, and real estate transactions to commercial litigation cases – G&M routinely receives accolades for its extensive restructuring and bankruptcy practice. G&M's restructuring professionals have extensive experience in workout negotiations, reorganizations, bankruptcy litigation, and debtor-creditor relations. Whether it is an out-of-court restructuring, workout advice, pre-bankruptcy counseling and planning, guidance through the chapter 11 process, or building leverage to maximize value for creditors, G&M's ability to provide top-tier counsel at affordable prices is without parallel.

Details Hidden

RTW Investments employs an event-driven investment strategy that focuses on long/short investments in US healthcare companies. The firm invests primarily in the stocks of: (1) pharmaceutical companies (2) medical device manufacturers and (3) diagnostic tool manufacturers. RTW Investments also makes select investments in derivatives and fixed-income instruments.

Recent Transactions
Details Hidden

REGENXBIO, Inc. issued USD Common Stock

Details Hidden

REGENXBIO, Inc. issued USD Common Stock

Details Hidden

REGENXBIO, Inc. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onREGENXBIO, Inc. issued Common Stock

Escrow Agent

Advised onREGENXBIO, Inc. issued USD Common Stock

Underwriter

Advised onREGENXBIO, Inc. issued USD Common Stock

Professional

Advised onREGENXBIO, Inc. issued USD Common Stock

Legal Advisor

Advised onREGENXBIO, Inc. issued USD Common Stock

Underwriter

Advised onREGENXBIO, Inc. issued USD Common Stock

Clients

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Key Stats and Financials As of 2018
Market Capitalization
$1.68B
Total Enterprise Value
$1.22B
Earnings Per Share
$2.73
Revenue
$219M
Net Profit
$99.9M
EBITDA
$92.1M
EBITDAMargin
42.14%
Total Debt
$5.85M
Total Equity
$509M
Enterprise Value Sales
5.6x
Enterprise Value EBITDAOperating
13.29x
TEVNet Income
12.24x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
206.51%
Five Year Compounded Annual Growth Rate Of Revenue
104.65%
Investments
Details Hidden

Dimension Therapeutics, Inc. engages in the provision of medical development. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz on October 2013, and is headquartered in Cambridge, MA.

Investors
Details Hidden

RTW Investments employs an event-driven investment strategy that focuses on long/short investments in US healthcare companies. The firm invests primarily in the stocks of: (1) pharmaceutical companies (2) medical device manufacturers and (3) diagnostic tool manufacturers. RTW Investments also makes select investments in derivatives and fixed-income instruments.

Details Hidden

Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. Perceptive Advisors advises two separate master-feeder private fund structures.The Perceptive Life Sciences Funds invest in the equities of growth healthcare companies and value plays, with an emphasis on biotechnology. Perceptive Advisors seeks to identify opportunities to exploit relative value disparities and inefficiencies that exist on both the long and short side of the market. They focus on a universe of about 300 smaller, more inefficiently priced companies which are underfollowed by Wall Street biotechnology analysts. Hedging strategies using long and short equity positions, equity options, and index options are used in an attempt to reduce and control risk.The Perceptive Credit Opportunity Fund seeks to achieve superior risk-adjusted returns by investing in senior secured loans and other debt and debt-related instruments issued by small- and mid-cap publicly traded companies and privately-held emerging growth companies primarily in the healthcare and related industries. The fund's investments may be originated by the fund or in collaboration with a syndicate of other credit investors. Most of the fund's investments will be structured as directly originated loans to healthcare companies.Perceptive Advisors also advises two separate accounts. The investment strategies of the separate accounts are substantially similar to those of the Perceptive Life Sciences Fund, though the separate accounts may take more concentrated positions and use a higher degree of leverage.

Details Hidden

Deerfield Management Co. LP (Private Equity) invests in a broad range of industries. It provides financing for buyout transactions to private and public companies located in the U.S.

Suppliers
GlaxoSmithKline Plc Medical Support Services | Brentford, Middlesex

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

University of Pennsylvania Investment Services & Portfolio Management | PHILADELPHIA, PA

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

FUJIFILM Holdings Corp. Equipment & Office Supplies | Tokyo, TY

FUJIFILM Holdings, Inc. engages in the development, production, sales and service of imaging, information, and document solutions. It operates through the following segments: Imaging Solutions, Information Solutions, and Document Solutions. The Imaging Solutions segment handles color films, digital cameras, optical devices, color paper, services and equipment for photofinishing, instant photo systems, etc. The Information Solutions segment deals with the equipment and materials for medical systems, life sciences products, pharmaceuticals, graphic arts, flat panel display materials, recording media and electronic materials, etc. The Document Solutions segment provides office copy machines/MFPs, printers, production systems and services, office services, paper and consumables, etc. The company was founded on January 20, 1934 and is headquartered in Tokyo, Japan.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

BioMarin Pharmaceutical, Inc. Pharmaceuticals - San Rafael, California

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by REGENXBIO, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of REGENXBIO, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and REGENXBIO, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/regenxbio-inc-206182
  • https://relationshipscience.com/organization/regenxbio-inc-206182